Derivative exercise or conversion — not an open-market buy.
Traded Jul 16, 2026 · Filed Jul 17, 2026
United Therapeutics's & GENERAL COUNSEL sold $1.75M of United Therapeutics shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$1,751,679
Shares × reported transaction price
71 days after results of May 6, 2026, 20 days before results of Aug 5, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
Derivative exercise or conversion — not an open-market buy.
CEO sold ~$627K of United Therapeutics
Scheduled in advanceCEO sold ~$665K of United Therapeutics
Scheduled in advance